News
The day at a glance · 3 min read
Mood · Cautious
-5
Sentiment, −100 to +100
Nxera Milestone Payment
$8.6M
Big Pharma & Biotech Pipeline
Abbott Price
$110.47+1.41%
MedTech & Diagnostics Performance
Amgen 5-Year Return
134.2%
Looking Ahead
Key driverClinical safety pause in cell therapy development balanced against managed care access expansion
Daily briefHealthcare· Money365.Market AI ·

Cell Therapy Setback, Managed Care Shift in Focus

Bristol Myers pauses autoimmune cell therapy trials on safety concerns while UnitedHealth removes prior authorization barriers across multiple services

Big Pharma & Biotech Pipeline

Neutral
01BMY
Bristol Myers Squibb ($BMY) has voluntarily paused enrollment in its zola-cel cell therapy trials for autoimmune conditions following inflammatory side effects detected during ongoing safety surveillance. The move raises questions around the risk profile of cell-based therapies in autoimmune diseases and the pace of $BMY's clinical pipeline development. Meanwhile, Eli Lilly ($LLY) subsidiary Centessa Pharmaceuticals achieved a late-stage development milestone associated with its selective orexin receptor 2 agonist portfolio, triggering an $8.6 million payment to Nxera Pharma pursuant to their research collaboration.
02AMGN
Amgen ($AMGN) and AstraZeneca reported positive Phase 3 CROSSING results showing TEZSPIRE improved histologic remission and dysphagia symptoms in patients with eosinophilic esophagitis, with effects sustained through week 52 and a safety profile broadly consistent with prior use.

Managed Care & Access Policy

Bullish
01UNH
UnitedHealthcare, the insurance business of UnitedHealth Group ($UNH), will remove prior authorization requirements for a broad range of healthcare services beginning October 1. The changes will cover areas including cardiology, genetic and laboratory testing, chiropractic care, physical, occupational and speech therapy, and orthopedic and musculoskeletal procedures. The policy shift will apply to commercial plans, Medicare and other product lines, representing a significant expansion of patient access without administrative barriers. The move marks a notable departure from industry practice around utilization management controls.

Drug Pricing & Regulatory Developments

Neutral
LLY
01
President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S. with international prices, bringing the total to 26 companies. The companies include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL and others. The expansion of voluntary pricing agreements continues the administration's approach to addressing drug cost concerns through negotiated arrangements rather than statutory price controls.
02LLY
$LLY is among the companies participating in the broader pricing initiative.

MedTech & Diagnostics Performance

Neutral
01ABT▲ +1.41%
Abbott Laboratories ($ABT) settled at $110.47, representing a 1.41% change from its previous close, exceeding market returns in the session. The medical device and diagnostics company continues to attract investor attention amid broader healthcare sector trading.
02ISRG
Intuitive Surgical ($ISRG) remains the undisputed leader in robotic surgery, though investors face questions about whether operational excellence justifies the premium valuation in the current market environment.

Looking Ahead

Neutral
01AMGN
Amgen ($AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 10, 2026. Thomas Dittrich, executive vice president and chief financial officer, Paul Burton, M.D., Ph.D, senior vice president and chief medical officer, and Kave Niksefat, senior vice president of Global Marketing and Access will present at the conference. Over the past 5 years, $AMGN has returned 134.2%, though current valuation checks send mixed signals as intrinsic value estimates suggest a discount while market-based multiples look closer to fair. The company's pipeline developments around Repatha and TEZSPIRE could support expectations for future cash flows.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy